Novitas says Pacific Edge’s CxBladder tests are ‘not payable’

Novitas says Pacific Edge’s CxBladder tests are ‘not payable’
The company can continue to apply for renewed coverage. (Image: Pacific Edge)
Rebecca Howard
The long-awaited draft Local Coverage Determination from Novitas is not good news for Pacific Edge’s US business. According to the determination (LCD), “CxBladder tests are not reasonable and necessary to support positive outcomes in the management of bladder cancer and, therefore, are not payable”.In June 2023, Pacific Edge confirmed that the LCD from Novitas — its Medicare administrative contractor — meant its flagship Cxbladder test for bladder cancer didn’t meet the threshold required for coverage un...

More Markets

Market ends week down but Briscoe defies guidance
Markets Market close

Market ends week down but Briscoe defies guidance

The S&P/NZX 50 Index is down 1.5% since the beginning of the year.

Briscoe Group downgrades FY guidance after slow December
Retail

Briscoe Group downgrades FY guidance after slow December

The downgrade comes ahead of Jan 26, when Briscoe's financial year ends.

NZ market remains in ‘limbo’ ahead of Trump‘s second term
Markets

NZ market remains in ‘limbo’ ahead of Trump‘s second term

The S&P/NZX 50 Index closed down 0.76% or 99.37 points to 12,944.

Tom Raynel 09 Jan 2025
Why James Miller is joining Fletcher’s board
Markets

Why James Miller is joining Fletcher’s board

James Miller says directors need to step up when companies face difficulties.